Contact
searchSearch
HMP Global
How I Treat
MASLD/MASH

How I Treat MASLD/MASH: A Sidney Barritt, MD

Sid Barritt
A Sidney Barritt IV, MD

Lifestyle Interventions: The Foundation of Management

Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic-associated steatohepatitis (MASH) are increasingly prevalent conditions. Despite recent advances in pharmacologic treatments, lifestyle intervention remains essential to effective treatment.

Dr Barritt describes his three-part appeal to patients when encouraging dietary and exercise modifications, and how to work with a multidisciplinary team to provide the support and credible information patients need to make these changes.

Sign up for our e-Newsletters

Gastroenterology Newsletter

News

Research Highlights
Incidence of Hepatocellular Carcinoma in MASLD Patients Quantified in Large Meta-Analysis
09/15/2025
Rebecca Mashaw
Robust pooled data highlight markedly increased hepatocellular carcinoma risk among MASLD patients with advanced fibrosis.
Robust pooled data highlight markedly increased hepatocellular carcinoma risk among MASLD patients with advanced fibrosis.
Robust pooled data highlight...
09/15/2025
Gastroenterology
FDA Alert
Obeticholic Acid Withdrawn From US Market for PBC; FDA Puts Clinical Trials on Hold
09/15/2025
Rebecca Mashaw
Intercept Pharmaceuticals will voluntarily withdraw its obeticholic acid product, Ocaliva, from the US market for the treatment of primary biliary cholangitis.
Intercept Pharmaceuticals will voluntarily withdraw its obeticholic acid product, Ocaliva, from the US market for the treatment of primary biliary cholangitis.
Intercept Pharmaceuticals will...
09/15/2025
Gastroenterology
Research Highlights
Analysis Challenges NordICC Trial Conclusions on CRC Screening and Mortality
09/05/2025
Rebecca Mashaw
The 10-year results from the NordICC study may underestimate the mortality benefits of screening colonoscopy due to inadequate follow-up time.
The 10-year results from the NordICC study may underestimate the mortality benefits of screening colonoscopy due to inadequate follow-up time.
The 10-year results from the...
09/05/2025
Gastroenterology
Research Highlights
Cumulative Social Risk Linked to Poorer Survival in Stage III Colorectal Cancer
09/05/2025
Rebecca Mashaw
A prospective cohort study found that each additional social risk factor significantly increased the likelihood of cancer-specific mortality among patients with advanced colorectal cancer.
A prospective cohort study found that each additional social risk factor significantly increased the likelihood of cancer-specific mortality among patients with advanced colorectal cancer.
A prospective cohort study found...
09/05/2025
Gastroenterology
Research Highlights
Fatty Pancreas Disease Linked to Elevated Risk of Pancreatic Cancer
09/04/2025
Jessica Garlewicz
The key takeaway for clinicians is the importance of recognizing fatty pancreas disease as more than an incidental imaging finding.
The key takeaway for clinicians is the importance of recognizing fatty pancreas disease as more than an incidental imaging finding.
The key takeaway for clinicians...
09/04/2025
Gastroenterology
News
Hypertension Linked to Liver Disease Progression and Adverse Outcomes in MASLD
09/04/2025
Jessica Garlewicz
Across three large prospective cohorts, hypertension was consistently associated with worse liver-related and systemic outcomes.
Across three large prospective cohorts, hypertension was consistently associated with worse liver-related and systemic outcomes.
Across three large prospective...
09/04/2025
Gastroenterology
News
GLP-1 Receptor Agonists Linked to Lower Risk of Peptic Ulcer Disease in Patients with T2DM
09/04/2025
Jessica Garlewicz
GLP-1 RAs may offer additional protection against gastrointestinal complications among patients with type 2 diabetes mellitus.
GLP-1 RAs may offer additional protection against gastrointestinal complications among patients with type 2 diabetes mellitus.
GLP-1 RAs may offer additional...
09/04/2025
Gastroenterology
FDA alert
FDA Alert
FDA Approves Semaglutide for MASH With Advanced Fibrosis
08/21/2025
Rebecca Mashaw
The first pharmacologic option authorized by the agency for MASH with moderate to severe fibrosis addresses a growing public health challenge.
The first pharmacologic option authorized by the agency for MASH with moderate to severe fibrosis addresses a growing public health challenge.
The first pharmacologic option...
08/21/2025
Gastroenterology
News
Racial Disparities Persist in Colorectal Cancer Outcomes
08/12/2025
Rebecca Mashaw
Despite significant advances in colorectal cancer screening and treatment, systemic inequities continue to drive higher incidence and mortality rates among Black Americans compared with White individuals, according to a recent review.
Despite significant advances in colorectal cancer screening and treatment, systemic inequities continue to drive higher incidence and mortality rates among Black Americans compared with White individuals, according to a recent review.
Despite significant advances in...
08/12/2025
Gastroenterology
News
Over 20 Years of Colorectal Cancer Disparities Reveal Racial and Regional Gaps in US Mortality
08/08/2025
Riya Gandhi, MA
Despite national declines in colorectal cancer deaths, a 20-year study finds Black men and residents of Southern and Midwestern states continue to face disproportionately high mortality rates.
Despite national declines in colorectal cancer deaths, a 20-year study finds Black men and residents of Southern and Midwestern states continue to face disproportionately high mortality rates.
Despite national declines in...
08/08/2025
Gastroenterology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use